Stocks To Buy Today, Feb 10: BSE, Mahanagar Gas, Jyothy Labs, Star Cement and others

Stocks to Buy Today

Nuvama on BSE: Maintain Buy with target price of Rs 3,760 raised from Rs 3,130

• Index options market share rose sharply despite the expiry shift to September 25
• Options ADPTV gains drove strong revenue momentum
• Operating leverage lifted EBITDA margins materially
• Profit growth supported by strong other income
• January options activity showed further acceleration
• Market share expansion proving structurally sticky
• Higher SGF and technology costs offset by lower clearing and staff costs
• CDSL stake continues to add valuation support

Citi on Mahanagar Gas

• Maintain BUY
• Target Price: Rs1,610
• 3QFY26 EBITDA beat (+14% vs est) driven by margin-led performance
• Margins resilient despite HP gas, currency and tariff headwinds
• Volume growth steady; inline with expectations
• Valuations undemanding; maintain Buy

Citi on India Shelter Finance

• Maintain BUY
• Target Price: Rs1,120
• Asset quality weakened; 30+ DPD/GNPA deteriorated in 3Q
• Growth moderating but spreads expanding support profitability
• Credit costs guided at higher end but manageable
• Risk-reward remains favourable; maintain Buy

ELARA on Star Cement

• Maintain BUY
• Target Price: Rs302
• Margin leadership continues; EBITDA/tonne at Rs1,562, fourth straight quarter of sector-leading margins
• Q3FY26 EBITDA up ~94% YoY, ~6% QoQ; beat driven by strong volume growth and lower power & fuel costs
• Volumes up ~21% YoY; among the highest growth rates in cement coverage
• Capacity ramp-up and new expansion announcements to support medium-term volume growth
• FY26E EBITDA raised ~5%; FY27–28 estimates unchanged
• Valuation rolled to Dec-27E at 12x EV/EBITDA; reiterate Buy
• Key risks: weak demand recovery, cement price pressure, spike in fuel costs

Goldman Sachs on Neuland Labs

• Maintain BUY
• Target Price: Rs17,325 (cut from Rs18,800)
• 3QFY26 Sales/EBITDA grew 10%/1% YoY, below expectations due to GDS shipment slowdown
• CMS segment strong with 74% YoY growth led by top commercial projects
• EBITDA margin at ~20%, ~618bps below GSe due to adverse mix and operating deleverage
• FY27–28 EPS cut by 6–11% on CDMO revenue deferral and loss of Paliperidone revenues
• Despite downgrade, GS sees ~25% upside; reiterates Buy

Elara on Jyothy Labs

• Maintain BUY
• Target Price: Rs320 (cut from Rs390)
• 3Q revenue grew 5% YoY with 7.2% volume growth; value growth lagged due to promotions
• Fabric care, HI and personal care drove growth; dishwash remained weak
• Gross margin contracted 326bps YoY on price cuts and input cost inflation
• FY26–28 EPS cut by ~5–6% factoring lower EBITDA margins
• Margins remain key overhang, but volume outlook for FY27 remains strong

(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)